|
|
Vaccine Detail
|
Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant |
| Vaccine Information |
- Vaccine Name: Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007107
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CTLA4
gene engineering:
- TNFRSF18
gene engineering:
- Preparation: mRNA used encodes anti-CTLA4 mAbs and GITR-stimulating molecules (Pruitt et al., 2011).
- Description: This is for Melanoma Cancer (NCT01216436). A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine (Gupta et al., 2015; NCIT_C2430).
|
| Host Response |
|
|
| References |
Gupta et al., 2015: Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015; 33(38); 4798-4806. [PubMed: 26241951].
NCIT_C2430: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2430]
NCT01216436: [https://clinicaltrials.gov/ct2/show/NCT01216436]
Pruitt et al., 2011: Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. European journal of immunology. 2011; 41(12); 3553-3563. [PubMed: 22028176].
|
|
